Drug Database
BR

brucellosis vaccine

✓ Approved

China National Pharmaceutical · 细胞治疗 · 细胞治疗

什么是 brucellosis vaccine?

brucellosis vaccine 是一种细胞治疗,由China National Pharmaceutical研发。该药已获批,用于治疗相关适应症,给药途径:Transdermal。

药物档案

公司China National Pharmaceutical
药物类别细胞治疗, 疫苗
给药途径Transdermal
状态Approved

治疗适应症

brucellosis vaccine 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsBrucellosis✓ Approved

相关研究文献

PubMedMolecular imaging and biology2026-11-18

Tracking Brucella abortus Infection in Immunized Mice Using In Vivo Bioluminescence Imaging.

Tarahomjoo Shirin S, Etemadi Afshar A, Alamian Saeed S

Brucella is the pathogen responsible for brucellosis, an important zoonotic illness, which affects humans and livestock worldwide. Currently, animal vaccination is used to prevent transmission of brucellosis from livestock to humans. The spread of luminous bacteria in laboratory animals can be monitored by bioluminescence imaging (BLI). In this study, therefore, we aim to develop an in vivo BLI strategy for assessing the immunogenicity of the brucellosis Rev1 vaccine, taking its benefits of shorter assay duration and reduced safety risks for the laboratory personnel. We have constructed a recombinant Brucella abortus 544 (BAPGH5) in which the firefly luciferase is expressed under the control of the PgroE promoter using the pPGH6-BSF22 plasmid. The parB locus was included in the plasmid to stabilize it in the absence of the antibiotic. The recombinant Brucella showed intense bioluminescence in vitro without using the antibiotic typically used for plasmid maintenance. It exhibited better growth compared to the parental strain. BAPGH5 showed strong bioluminescence in vivo when administered to mice intraperitoneally and colonized the mice spleens at a level comparable to that of the parental strain administered at the standard dose for the Rev1 vaccine immunogenicity testing. The recombinant Brucella isolated from the mice spleens showed strong bioluminescence, indicating in vivo stability of the pPGH6-BSF22 plasmid. The dissemination pattern of BAPGH5 in mice immunized with the Rev1 vaccine was clearly distinct from that of the control mice, as revealed by BLI. These results suggest the usefulness of the developed in vivo BLI strategy for assessing the immunogenicity of the Rev1 vaccine.

PMID 43045947
阅读全文 →
PubMedChina CDC weekly2026-11-18

Childhood Immunization Schedule for National Immunization Program Vaccines, China (Version 2026).

Administration National Disease Control And Prevention NDCAP, China National Health Commission Of The People's Republic Of NHCOTPRO

In June 2026, the National Disease Control and Prevention Administration and the National Health Commission issued the Childhood Immunization Schedule for National Immunization Program Vaccines (Version 2026). Compared with the 2021 version, the key updates include optimization of the five-dose Diphtheria-Tetanus-acellular Pertussis vaccine schedule (with the first dose advanced to 2 months of age and the fifth dose administered at 6 years of age); inclusion of the bivalent human papillomavirus vaccine in the National Immunization Program as a two-dose series for girls aged 13 years (Table 1); and expanded and refined vaccination guidance for children with medical conditions, including preterm and low-birthweight infants, children with allergies, children born to mothers living with human immunodeficiency virus, children with immune function abnormalities, jaundice, common congenital diseases, or common neurological diseases, and children receiving blood products. This English translation provides a reference for public health professionals.

PMID 43047791
阅读全文 →
PubMedNature communications2026-11-18

Short-term effectiveness and impact of Vaxchora vaccine during the 2024 cholera outbreak in Mayotte.

Brault Antoine A, Herry François F, Mazzilli Sara S, Cristancho-Fajardo Lina L et al.

Global cholera resurgence and vaccine shortage have driven the adoption of reactive one-dose strategies with killed oral cholera vaccines (OCVs). The live-attenuated vaccine CVD 103-HgR (Vaxchora) shows high efficacy in human challenge studies, but its real-world effectiveness in outbreaks is unknown. Here, we analyze the 2024 outbreak in Mayotte, focusing on Koungou village, which had high cholera incidence and vaccine uptake. We develop several stochastic models and calibrate them to daily cases by vaccination status. In total, 3354 individuals (71%) of Koungou's at-risk population (n = 4733) received CVD 103-HgR, and 77 cases were confirmed, with symptom onset between 19 April and 7 July 2024. At baseline, we estimate a basic reproduction number R 0 of 1.5 (95% credible interval (CrI): 1.2, 1.9) and a CVD 103-HgR effectiveness in preventing cholera of 87% (95% CrI: 74, 99), remaining between 75% and 91% across scenarios. Counterfactual simulations estimate 536 (95% CrI: 240, 824) cases averted at baseline, with a range of point estimates from 152 to 1228 across sensitivity analyses. Rapid single-dose CVD 103-HgR deployment is associated with high effectiveness during a real‑world outbreak, with a substantial but more uncertain population impact, supporting the inclusion of live-attenuated OCVs in reactive strategies when necessary.

PMID 43045698
阅读全文 →
PubMedChina CDC weekly2026-11-18

National Survey of Weight Management Knowledge and Behaviors Among Adults Aged 18-64 Years - China, 2024-2025.

Ding Caicui C, Yuan Fan F, Qiu Yujie Y, Wu Xinyue X et al.

Overweight and obesity are major public health challenges in China; national data on adult weight management knowledge and behaviors remain limited. In this 2024-2025 national survey (n=68,579), knowledge awareness was 46.5% and behavioral compliance only 18.0%, with a marked knowledge-action gap and socioeconomic disparities. Targeted health education prioritizing vulnerable groups is needed to convert knowledge into weight management behaviors.

PMID 43048004
阅读全文 →
PubMedChina CDC weekly2026-11-18

Reported Cases and Deaths of National Notifiable Infectious Diseases - China, September 2026.

PMID 43047715
阅读全文 →
PubMedBioinformatics and biology insights2026-11-18

Formulation of a Novel NS5A- and NS5B-Based Chimeric Vaccine Against Hepatitis C Virus: An Artificial Intelligence-Supported Approach.

Niknam Maryam M, Zohrabzadeh Maryam M, Hahashempour Ava A, Honari Jahromi Ali A et al.

We aimed to design a multiepitope vaccine against hepatitis C virus (HCV) with the potential to elicit broad protective immunity against diverse HCV genotypes through computational design.Method: One hundred sequences of the most widespread subtypes of HCV were retrieved from the Los Alamos National Laboratory database, and consensus sequences of the NS5A and NS5B proteins were generated to construct an efficient vaccine for human use. Numerous B-cell lymphocyte, cytotoxic T-lymphocyte and helper T-lymphocyte epitopes located in the conserved domains of HCV proteins and similar in human and mouse alleles were evaluated criteria for use in the vaccine construct. Population coverage analysis identified that substantial parts of the worldwide population carry epitopes and their corresponding alleles within their genome, which confirms that the vaccine candidate is an effective agent against this lethal disease. Codon optimization and in silico cloning of eukaryotic and prokaryotic vectors validated the strong expression of the vaccine construct in the host systems. Molecular docking analysis revealed favorable binding affinities between the vaccine construct and toll-like receptors, which confirmed the vaccine's capacity to induce robust and stable immune responses against the hepatitis C virus. We incorporated new bioinformatic methods to design multiepitope vaccine against HCV. The development of a vaccine targeting multi genotypes of HCV could potentially provide for long-term protection against infection and may mitigate the risk of drug resistance across various genotypes and subtypes. Current research emphasizes the need for a vaccine that can elicit comprehensive immune responses, including both neutralizing antibodies and T-cell responses, to effectively address the genetic diversity of the virus. Future experimental studies are essential to validate predicted immunogenicity, structural stability, and protective efficacy before clinical consideration.

PMID 43047676
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多brucellosis vaccine